TAVR Emerging As Next Big Application For Embolic Protection Devices
Executive Summary
Studies suggest transcatheter aortic valve replacement is associated with a higher stroke risk than standard surgical valve replacement, presumably due to embolic debris released during the TAVR procedure. To address this concern, several companies are developing TAVR-specific embolic protection devices, and their success may prove to be a key driver of future growth in this $1+ billion market.
You may also be interested in...
Stroke Prevention For TAVR – And, Perhaps, Beyond
Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.
Stroke Prevention For TAVR – And, Perhaps, Beyond
Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.
News Briefs: Panel OKs Sleep Apnea Stimulator; Two Stryker Buys; TAVR Updates
FDA panel unanimously endorses Inspire upper airway stimulator. Stryker buys Berchtold and Pivot. First randomized U.S. study of embolic protection during transcatheter aortic valve replacement approved. More news.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: